UNSPSC 51422430: Hydrocortisone hemisuccinate anhydrous

This classification denotes an anti-inflammatory agent with the molecular formula C25H34O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IHV1VP592V, chemically known as cortisol 21-(hydrogen succinate), but more generally known as hydrocortisone hemisuccinate anhydrous, which bears US NIH Compound Identifier 16623. European Medicines Agency schedules hydrocortisone hemisuccinate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG.

Most nations, for tariff purposes, schedule hydrocortisone hemisuccinate anhydrous under HS 29372100. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)O)O)C)O.

UNSPSC 51422430 Hydrocortisone hemisuccinate anhydrous is a Commodity code, but the recent state and local opportunities posted under it show little alignment with the code's pharmaceutical scope. The Seminole County, Florida IFB solicitation (IFB60459723LAS, due Jul 26, 2023) procures naloxone and drug deactivation systems rather than hydrocortisone, while the Texas Health and Human Services Commission RFI (HHS0017013, posted Apr 3, 2026) explores direct-to-manufacturer prescription fulfillment models without specifying hydrocortisone or related corticosteroids. The code shows limited recent activity among state and local buyers, and the posted opportunities do not reflect procurement of hydrocortisone hemisuccinate or pharmaceutical raw materials typically classified under this commodity.

The geographic spread of recent activity is narrow, limited to Florida and Texas. Issuing bodies include county health departments (Seminole County) and state health and human services agencies (Texas HHS Commission). Neither opportunity provides substantive signals for firms pursuing contracts under this code — the Seminole County IFB targets emergency response supplies outside the code's pharmaceutical scope, and the Texas RFI remains exploratory without formal competitive detail or budget parameters. Firms evaluating this code should monitor activity in state pharmacy benefit programs and county public health procurement channels, but current opportunities do not suggest near-term demand for hydrocortisone hemisuccinate specifically.